Biotechnology

With new Phase 3 data for inactive thyroid eye disease, Innovent Biologics is solidifying a domestic moat against foreign biotech rivals in China.

A landmark 6,000-person trial by Holobiome and Radicle Science is utilizing AI and decentralized testing to see if food can solve anxiety.

By bypassing the blood-brain barrier, AviadoBio's novel gene therapy halts key neurodegeneration markers in a devastating form of genetic dementia.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

A breakthrough gene therapy restores natural hearing in children, challenging mechanical implants and reshaping the economics of genomic medicine.

Jack Patterson examines how new off-the-shelf CAR T-cell therapy and optimized monoclonal antibodies could disrupt the multiple sclerosis treatment paradigm.

Tech elites are pouring billions into reversing aging, but top scientists at an exclusive retreat just delivered a surprising reality check on human lifespan.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Oncodesign Precision Medicine is advancing its LRRK2 inhibitor OPM-201 toward Phase 1b. Here is how strategic repatriation and non-dilutive funding are paving the commercial pathway.

The Food Allergy Science Initiative is shifting from basic research to biotech incubator, launching a $10M accelerator to turn academic discoveries into drugs.

As the Progeria Research Foundation honors pioneer David R. Liu and philanthropists Cathy and Dave Gravel, the ultimate biological network upgrade approaches clinical reality.

Ahead of a critical 2027 data readout, Moleculin pitches a breakthrough leukemia drug while navigating a precarious financial runway.

AmyriAD Therapeutics is betting an all-stock deal can turn a missed Phase 2b endpoint into a breakthrough for cognitive impairment in schizophrenia.

An inside look at how Pure Capital Group leveraged Israeli corporate law and financial vulnerabilities to seize control of an AI biotech pioneer without a buyout.

BridgeBio is using cultural icons to find undiagnosed heart disease in Black men. It’s a brilliant public health move—and a shrewd business strategy.

In an era of pharmaceutical supply chain disruptions and rising FDA warning letters, one manufacturer's pristine compliance streak offers a rare blueprint.

C5 Biomedical CEO Tim Maye is recognized among the AATB's '50 at 50' honorees, highlighting the crucial link between industry standards and commercial success.

GC Cell and QuantHealth are deploying predictive AI to simulate clinical trials, aiming to de-risk development and protect capital in cell therapy.

As the FDA accelerates rare disease approvals, a Boston startup is turning biomanufacturing cleanrooms into plug-and-play products powered by AI.